| 11.6 1.6 (16%) | 10-24 14:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.41 |
1-year : | 16.83 |
| Resists | First : | 12.34 |
Second : | 14.41 |
| Pivot price | 9.94 |
|||
| Supports | First : | 8.71 |
Second : | 6.46 |
| MAs | MA(5) : | 10.97 |
MA(20) : | 9.61 |
| MA(100) : | 6.32 |
MA(250) : | 5.57 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 70.6  |
D(3) : | 75.9 |
| RSI | RSI(14): 69.7 |
|||
| 52-week | High : | 12.34 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FDMT ] has closed below upper band by 0.6%. Bollinger Bands are 108.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.74 - 10.83 | 10.83 - 10.89 |
| Low: | 9.78 - 9.87 | 9.87 - 9.93 |
| Close: | 9.88 - 10.02 | 10.02 - 10.12 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Tue, 21 Oct 2025
RBC Capital Reiterates 4D Molecular Therapeutics (FDMT) Outperform Recommendation - Nasdaq
Tue, 21 Oct 2025
FDMT: RBC Capital Reiterates Outperform Rating with $26 Price Ta - GuruFocus
Mon, 20 Oct 2025
Bizily, 4D Molecular Therapeutics CLO, sells $16,627 in FDMT stock - Investing.com
Fri, 17 Oct 2025
25,450 RSUs: 4DMT Grants Stock Awards to Three New Employees Under 2025 Inducement Plan - Stock Titan
Fri, 17 Oct 2025
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? - Yahoo Finance
Tue, 14 Oct 2025
4D Molecular Therapeutics to Participate in Chardan’s 9th Annual Genetic Medicines Conference Panel Discussions - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 3.57e+007 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 4,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1582e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -396 % |
| Return on Assets (ttm) | 373.3 % |
| Return on Equity (ttm) | -25.2 % |
| Qtrly Rev. Growth | 33000 % |
| Gross Profit (p.s.) | 68.49 |
| Sales Per Share | -13.32 |
| EBITDA (p.s.) | -5.82842e+007 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -166 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.9 |
| Price to Cash Flow | 3.84 |
| Dividend | 0 |
| Forward Dividend | 4.49e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|